Due to budget adjustments made in USA as well as cost containment measures in European countries
Friday September 26, 2014 / El Global
According to the information collected by the Reuters agency and the specialized portal Pharma Times, the German pharmaceutical company Boehringer Ingelheim announced its intention to make a total of 600 redundancies in Germany. To justify this decision, the company allegedly appealed to budget adjustments made in the USA (its largest market with over 5,000 million euros in revenues in 2013), as well as cost-containment measures in European countries. These measures, together with the loss of some patents and currency effects led to almost 4 percent of the German company's sales decline in 2013.
In the photo: Prof. Dr Andreas Barner, Corporate Board Divisions Human Resources, Research & Development and Medicine
Related news: Boehringer Ingelheim to pay $650 million to settle nearly 4,000 US lawsuits related to Pradaxa
Boehringer plans to cut thousands of jobs
